Volume | 154,555 |
|
|||||
News | - | ||||||
Day High | 0.19 | Low High |
|||||
Day Low | 0.17 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Scorpius Holdings Inc | SCPX | AMEX | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.1714 | 0.17 | 0.19 | 0.176565 | 0.1758 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
500 | 154,555 | US$ 0.1768489 | US$ 27,333 | - | 0.145 - 0.53 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
19:00:00 | 100 | US$ 0.176565 | USD |
Scorpius Holdings Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
4.69M | 26.08M | - | 7M | -45.22M | -1.73 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Scorpius News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SCPX Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.183 | 0.20 | 0.165 | 0.1792685 | 348,434 | -0.0005 | -0.27% |
1 Month | 0.165 | 0.246 | 0.157 | 0.1963076 | 700,012 | 0.0175 | 10.61% |
3 Months | 0.35 | 0.53 | 0.145 | 0.1983949 | 707,326 | -0.1675 | -47.86% |
6 Months | 0.4198 | 0.53 | 0.145 | 0.2013677 | 633,655 | -0.2373 | -56.53% |
1 Year | 0.4198 | 0.53 | 0.145 | 0.2013677 | 633,655 | -0.2373 | -56.53% |
3 Years | 0.4198 | 0.53 | 0.145 | 0.2013677 | 633,655 | -0.2373 | -56.53% |
5 Years | 0.4198 | 0.53 | 0.145 | 0.2013677 | 633,655 | -0.2373 | -56.53% |
Scorpius Description
NightHawk Biosciences is a fully integrated biopharmaceutical company focused on the development of new drugs from discovery through commercialization. The Company leverages its integrated ecosystem of subsidiaries to accelerate the creation and manufacture of novel therapies that arm the immune system, breaking through barriers that prolong traditional drug development. This empowers us to bring our ideas to life with efficient control, superior quality, and uncharacteristic agility. |